Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Urine pharmacokinetic variables of lucerastat

From: Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects

Study Dose regimen   Ae 0-12h [21] Ae 12-24h [21] Ae 0-24h [21] % of dose
SAD 100 mg   47 (21) 6 (4) 53 (24) 53 (24)
300 mg   145 (52) 10 (6) 153 (54) 49 (20)
500 mg   256 (24) 24 (12) 280 (12) 56 (6)
1000 mg   452 (122) 49 (46) 501 (98) 50 (10)
2x1000 mg   524 (50) 304 (191) 904 (295) 45 (15)
MAD 200 mg Day 7 160 (14) 145 (31) 305 (40) 76 (10)
500 mg Day 7 357 (64) 362 (56) 719 (101) 72 (10)
1000 mg Day 7 864 (243) 830 (152) 1695 (289) 85 (15)
  1. Data are arithmetic means (standard deviation); Ae cumulative amount of unchanged drug excreted in urine, SAD single ascending dose, MAD multiple ascending dose